Nielsen: Vape Sales Decline in U.S., Vuse Market Share Slightly Rising to 42.2%

Market by 2FIRSTS.ai
Mar.06.2024
Nielsen: Vape Sales Decline in U.S., Vuse Market Share Slightly Rising to 42.2%
According to Journalnow, e-cigarette sales in the US have dropped 13.9%, with Vuse by R.J. Reynolds gaining market share.

According to a recent report by Journalnow, data released by Nielsen Convenience Store shows that overall e-cigarette sales in the United States have decreased by 13.9%.

 

Among them, the market share of the best-selling e-cigarette brand Vuse, owned by British American Tobacco subsidiary R.J. Reynolds, has gradually increased from 42% to 42.2%; while the second-ranked JUUL's market share remains unchanged at 24.2%; the market share of NJoy, acquired by Ascent Industries, has reached 3.2%; and the market share of blu eCigs, owned by Imperial Tobacco subsidiary Fontem Ventures, has decreased from 1.2% to 1.1%.

 

In 2019, JUUL held a market share of 74.6% in the e-cigarette market in the United States. However, a series of regulatory actions have led to a reduction in product availability and a decrease in consumer demand.

 

British American Tobacco and Imperial Brands are urging the Food and Drug Administration (FDA) to crack down on the illegal synthetic nicotine e-cigarette products in the US tobacco market. The two companies estimate that these synthetic tobacco products account for half of the entire e-cigarette market in the United States.

 

The Nielsen report primarily focuses on large chain stores, while for small chain stores, the organization relies on trend extrapolation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%
Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%
Imperial Brands reported FY25 NGP net revenue of £368 million, up 13.7% at constant currency. Growth in the Americas accelerated sharply, with NGP revenue up 69.8%, driven by the expansion of the modern oral brand Zone. Europe delivered 8.8% growth, supported by blu’s double-digit vapour share across key markets. Adjusted NGP operating losses narrowed to £76 million, putting the category closer to breakeven.
Nov.18 by 2FIRSTS.ai
British American Tobacco’s VELO Launches Limited McLaren F1 Edition: US Price Only 60% of EU/UK
British American Tobacco’s VELO Launches Limited McLaren F1 Edition: US Price Only 60% of EU/UK
BAT’s VELO has released a McLaren F1 co-branded, track-themed limited-edition pack in McLaren’s orange-black livery. Pricing is about $4.60 per can in the U.S. versus ~$7.40 in the EU/UK. The collaboration extends BAT’s partnership with McLaren dating back to 2019.
Oct.11 by 2FIRSTS.ai
Ukraine intensifies crackdown on illicit tobacco and alcohol markets
Ukraine intensifies crackdown on illicit tobacco and alcohol markets
Ukraine’s State Tax Service (GNS) has carried out around 24,000 on-site inspections in the tobacco and alcohol sectors this year, imposing more than ₴795 million (US$194 million) in fines and revoking over 2,500 business licences.
Oct.17 by 2FIRSTS.ai
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian outlet Rebel News released a long-form video report examining Canada’s regulatory framework for nicotine pouches, market dynamics, and the approval process of ZONNIC, a product of BAT subsidiary Imperial Tobacco Canada. The report highlights issues involving youth access, regulatory gaps, black-market activity, retailer feedback, and company responses. This article summarizes key points based on the video.
Dec.02 by 2FIRSTS.ai
Japan Tobacco Announces Executive Leadership Changes Effective in 2026
Japan Tobacco Announces Executive Leadership Changes Effective in 2026
Japan Tobacco Inc. (JT) has announced a series of executive and board appointments effective from 2026, including the nomination of Takehiko Tsutsui—currently Executive Vice President at JT International—as President, CEO and Representative Director.
Nov.26
EU Cardiovascular Health Plan Consultation Highlights Tobacco Debate — 2Firsts Analysis Reveals Divide Between “Cessation” and “Harm Reduction” Approaches
EU Cardiovascular Health Plan Consultation Highlights Tobacco Debate — 2Firsts Analysis Reveals Divide Between “Cessation” and “Harm Reduction” Approaches
As the EU finalizes its Cardiovascular Health Plan, public feedback reveals a sharp divide over nicotine policy.A 2Firsts analysis of 677 submissions found that nearly one in four mentioned tobacco — highlighting tension between strict control and harm reduction approaches.
Oct.07